RDTCF (Rapid Dose Therapeutics) Accounts Payable: $1.58 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RDTCF Rapid Dose Therapeutics Corp RDTCF
29 GF Score
Price $0.09
GF Value $0.25
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics Accounts Payable?

Rapid Dose Therapeutics RDTCF +8.42% 29 Accounts Payable is $1.58 Mil as of Feb. 2026. GuruFocus rates RDTCF with a GF Score™ of 29/100 and a GF Value™ of $0.25 (Possible Value Trap). The stock has 3 warning signs investors should review.

Rapid Dose Therapeutics's Accounts Payable for the quarter that ended in Feb. 2026 was $1.58 Mil.

Rapid Dose Therapeutics's quarterly Accounts Payable declined from Aug. 2025 ($1.44 Mil) to Nov. 2025 ($1.30 Mil) but then increased from Nov. 2025 ($1.30 Mil) to Feb. 2026 ($1.58 Mil).

Rapid Dose Therapeutics's annual Accounts Payable increased from Feb. 2024 ($0.83 Mil) to Feb. 2025 ($1.36 Mil) and increased from Feb. 2025 ($1.36 Mil) to Feb. 2026 ($1.58 Mil).

Rapid Dose Therapeutics Accounts Payable Related Terms

Rapid Dose Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics Accounts Payable Chart

Rapid Dose Therapeutics Annual Data
Trend Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 2.07 0.83 1.36 1.58

Rapid Dose Therapeutics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.26 1.44 1.30 1.58
RDTCF
29GF Score
Rapid Dose Therapeutics Corp RDTCF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapid Dose Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.58 Mil mean?
Rapid Dose Therapeutics (RDTCF) has a Accounts Payable of $1.58 Mil as of Feb. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Rapid Dose Therapeutics and its competitors.
Is Rapid Dose Therapeutics' Accounts Payable too high?
Rapid Dose Therapeutics' current Accounts Payable is $1.58 Mil. Overall, Rapid Dose Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Accounts Payable compare to VRTX and REGN?
Rapid Dose Therapeutics' Accounts Payable of $1.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Rapid Dose Therapeutics and its competitors. Rapid Dose Therapeutics's current Accounts Payable is $1.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.25, compared to a current price of $0.09 — trading 66% below its estimated fair value. The current Accounts Payable is $1.58 Mil. Rapid Dose Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Accounts Payable is $1.58 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.09 is trading 66% below its estimated GF Value™ of $0.25. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • Accounts Payable: $1.58 Mil
  • GF Value™: $0.25 vs. price of $0.09 (66% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
29GF Score

Get the complete analysis for RDTCF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price
$0.25
GF Value